Compare MC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MC | GH |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 14.1B |
| IPO Year | 2014 | 2018 |
| Metric | MC | GH |
|---|---|---|
| Price | $71.44 | $103.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 21 |
| Target Price | $73.75 | ★ $96.48 |
| AVG Volume (30 Days) | 822.4K | ★ 1.8M |
| Earning Date | 02-04-2026 | 10-29-2025 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | ★ 446.16 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $1,467,580,000.00 | $902,569,000.00 |
| Revenue This Year | $27.08 | $35.00 |
| Revenue Next Year | $17.26 | $26.80 |
| P/E Ratio | $22.58 | ★ N/A |
| Revenue Growth | ★ 51.19 | 30.38 |
| 52 Week Low | $47.00 | $29.91 |
| 52 Week High | $82.89 | $112.43 |
| Indicator | MC | GH |
|---|---|---|
| Relative Strength Index (RSI) | 65.76 | 57.55 |
| Support Level | $69.51 | $96.28 |
| Resistance Level | $71.58 | $103.17 |
| Average True Range (ATR) | 1.91 | 3.53 |
| MACD | 0.22 | -0.70 |
| Stochastic Oscillator | 85.55 | 71.98 |
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.